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Abstract
Dengue virus infection presents a wide spectrum of manifestations including asymptomatic condition, dengue
fever (DF), or severe forms, such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) in
affected individuals. The early prediction of severe dengue in patients without any warning signs who may
later develop severe DHF is very important to choose appropriate intensive supportive therapy since available
vaccines for immunization are yet to be approved. Severe dengue responses include T and B cell activation
and apoptosis, cytokine storm, hematologic disorders and complement activation. Cytokines, complement and
other unidentified factors may transiently act on the endothelium and alter normal fluid barrier function of
the endothelial cells and cause plasma leakage. In this review, the host factors such as activated immune and
endothelial cells and their products which can be utilized as biomarkers for severe dengue disease are discussed.
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Introduction
Dengue is a mosquito borne viral infection found in
tropical and sub-tropical regions of the world and is
caused by one of the four serotypes of dengue viruses
(DENV1-DENV4). An increase in infection has been
seen in recent years due to many factors including
urbanization and air travel. Over 2.5 billion people of
the world’s population are now at risk for dengue. The
consequences of DENV infection range from asymptom-
atic condition, dengue fever (DF), or severe forms, such
as dengue hemorrhagic fever (DHF) and dengue shock
syndrome (DSS). Severe dengue is characterized either
by plasma leakage, fluid accumulation, respiratory dis-
tress, severe bleeding, or organ impairment [1]. Clinical
manifestations offer the earliest markers in predicting
severe dengue disease. A recent meta-analysis of signs
and symptoms of severe dengue shows that bleeding,
nausea and vomiting, abdominal pain, skin rashes, and
hepatosplenomegaly are associated with severe dengue
disease [2]. Patients with dengue fever are clustered into
two groups: one with warning signs including abdominal
pain, mucosal bleeding and liver enlargement that
warrant ICU admission and the other without those
signs [1, 2]. Early prediction of severe dengue in patients
without any warning signs who may later develop severe
DHF is very important to give the best supportive care since
approved vaccines for immunization are yet to be commer-
cialized. An ideal biomarker should be able to identify indi-
viduals who are at risk of developing severe dengue.
The mechanism by which only a few DENV infected
individuals progress to severe dengue disease is poorly
understood. The host immune responses have been con-
sidered as the major factor responsible for dengue
pathogenesis. The process of plasma leakage, shock and
hemorrhagic manifestations initiated by enhancing infec-
tion with DENV virus with the help of opsonizing anti-
bodies, resulting in an altered immune response which
trigger T cell activation and release of cytokines and
chemical mediators has been a risk factor in secondary
infection [3, 4]. However, undefined factors could play a
role in the development of severe dengue in individuals
with naïve primary infection and immune non-
responders [5]. Dengue patients show fever symptoms
during peak of viremia while DHF/DSS appears during
the time when the virus has been cleared from the circu-
lation suggesting severe dengue disease is most likely
associated with immunopathology. Thus, the host
immune response components including cells, cytokines,
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complements and other cellular mediators can serve as
biomarkers of severe disease [6, 7]. It is reported that
the macro-morphology of endothelial lining remains in-
tact while the functionality of the endothelial cells is al-
tered by activation which leads to vascular permeability
resulting in plasma leakage [8]. Therefore, endothelial
activation markers such as expression of adhesion mole-
cules and receptors can also serve as biomarkers of se-
vere dengue disease [9, 10]. In this review, the various
host immune and endothelial activation markers and
biochemical and genetic markers are reviewed for their
utility as potential biomarker of severe dengue disease.
Immune activation markers as predictors of severe
dengue disease
Number and activation status of immune cells
DENV has been shown to infect a wide range of cells in-
cluding dendritic cells (DCs), monocytes, lymphocytes,
hepatocytes, endothelial cells (ECs) and mast cells in
vitro [6]. Although the role of these cells in DENV infec-
tion remains less clear in vivo, activation of memory T
cells resulting in cascades of inflammatory cytokines and
other chemical mediators that trigger death of target
cells through apoptosis is a critical element contributing
to severe dengue [11]. DCs and macrophages are the pri-
mary targets of DENV infection [12, 13]. Both the abso-
lute number and frequency of circulating myeloid DCs
(mDCs) and plasmacytoid DCs (pDCs) were decreased
early in acute viral illness in children but not in adults
who subsequently developed DHF and decreased level of
pDCs was associated with higher viremia levels [14, 15].
Activated DCs may contribute to vascular leak through the
production of TNF-α, IFN-γ and matrix metalloproteases-
2, 3 and 9 [16, 17]. Studies show that CD4 T cell, CD8 T
cell, NK cell and γδ T cell counts were significantly de-
creased in DHF compared to DF early in the course of ill-
ness [18]. The CD8 T cells and NK cells from dengue
patients displayed activation markers such as CD69,
HLA-DR, CD38 and cytotoxic granule TIA-1 and cell
adhesion molecules CD44 and CD11a during the
acute phase [19, 20]. The decreased numbers of lym-
phocytes could be due to increased apoptosis of per-
ipheral blood mononuclear cells observed during
DENV infection evidenced by the presence of in-
creased plasma levels of soluble CD95, a mediator of
apoptosis, and down-regulation of the antiapoptotic
protein Bcl-2 in these cells [21, 22]. Cross-reactive
memory T cells that are highly activated with increased
levels of cytokine producing capacity was observed in pa-
tients with acute dengue disease. Activation of cross-
reactive low affinity T-cells results in copious amounts of
cytokine and chemokine production such as IFN-γ, TNF-
α, IL-1, IL-6, IL-8, IL-10, CCL2 (MCP-1) and CCL5
(RANTES) [23, 24].
Activation of mast cells and increased levels of urinary
histamine, which is a major product of mast cells were
observed in dengue patients and the levels correlated
with disease severity [25]. Several data indicated that
virus stimulated mast cells selectively produced and
secreted a variety of mediators including chemokines,
cytokines, lipid mediators, and granule associated prod-
ucts. Elevated levels of secreted CCL3 (MIP-1α), CCL4
(MIP-1β) and CCL5 were observed following infection
of human mast cell lines [26, 27]. Substantial levels of
tryptase and chymase were found in mast cells and these
proteases are considered to be selective markers of mast
cell activation. Plasma levels of both tryptase and chy-
mase were increased significantly in DHF/DSS compared
with DF. [28] Thrombocytopenia is one of the clinical
hallmarks for dengue patients. There are many mecha-
nisms leading to the depletion of platelets in affected
subjects, these include direct infection of megakaryo-
cytes by DENV as well as platelet destruction due to
nonstructural protein 1 (NS1) binding and platelet-asso-
ciated antibodies [29–31]. Thrombocytopenia is best used
as a marker of severe disease particularly when it is
<100,000 cells/c.mm and serve as an indicator of
prognosis during the course of the disease [18, 32, 33].
Since thrombocytopenia is seen in both DF and DHF
patients, a platelet count of 60,000 cells/c.mm serves as a
better cut-off in identifying more severe cases [7].
Increased levels of cytokines and chemokines
Patients with DHF/DSS present a ‘cytokine storm’, with
high levels of circulating cytokines and chemokines.
Therefore, serum cytokine and chemokine levels can
serve as a laboratory tool for predicting severe disease. T
cells, NK cells, monocytes, macrophages, hepatocytes
and ECs have been shown to contribute to the increased
production of cytokines and chemokines. Increased
levels of IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-
10, IL-13, IL-15, IL-17, IL-18, macrophage migration in-
hibitory factor (MIF) and chemokines CCL2, CCL4,
CCL5, and CXCL10 (IP-10) have been reported in pa-
tients with DHF when compared to DF. [34–38] Studies
show that elevated levels of IL-6, IL-10, IFN-γ, MIF, and
CCL-4 could be used as potential predictors of severe
dengue [39–46].
Complement, antibodies and other soluble factors
Complement activation and an increase in complement
protein products correlate with severe dengue disease
[47]. Large amounts of C3, C3a and C5a have been
detected in DENV-infected patients and determining
their levels in serum is important since these anaphyla-
toxins direct the lysis of infected cells and mast cell
degranulation leading to histamine release [48, 49].
An increase in the number of B lymphocytes was
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demonstrated in DHF. [18] Total and dengue-specific
IgE antibody levels were higher in patients with DHF
and DSS compared with those with DF. [50] NS1 is
an immunogen and high concentrations of anti-NS1
antibodies have been found in severe disease. Anti-
bodies to NS1 can cross-react with human ECs and plate-
lets and cause vascular permeability with production of
nitric oxide (NO) and apoptosis [51, 52]. Determining the
levels of dengue-specific IgE, anti-platelet and anti-EC
antibodies might be used as biomarkers of severe dengue
disease. Soluble factors are more stable and have the po-
tential to serve as biomarkers. Increased levels of soluble
receptors such as sTNFRII, sCD4, sCD8, sIL-2R were re-
ported in DHF patients when compared to those with DF
and that their levels correlated with disease severity [18,
53]. Release of sTNFR may be an early and specific marker
of the endothelial changes that cause DSS [42]. The IL-1
receptor-like-1 protein (IL1RL1), also known as ST2, is a
member of the IL1R/Toll-like receptor (TLR) superfamily.
Increased serum sST2 was found in patients having
secondary infection and DHF patients compared to
DF patients and may be a predictive marker of den-
gue severity [44, 54].
Endothelial activation markers as predictors of
severe dengue disease
Endothelium is the ultimate target of permeabilizing re-
sponses and DENV influence on ECs may be direct or
indirect by the release of mediators from infected or ac-
tivated immune cells. DENV antigens associated with
ECs were observed in autopsy samples in liver, spleen,
kidney and lungs from DHF/DSS patients and infection
of primary ECs by DENV has been reported [55, 56].
DENV infected ECs produce chemokine and cytokine
responses that activate or recruit immune cells to the
endothelium [57, 58]. Uncontrolled and persisted activa-
tion of endothelium leads to vascular permeability,
microvascular thrombosis and inflammation and thus
the components of activated endothelium in serum and/
or plasma can serve as biomarkers of severe dengue dis-
ease [10, 59]. Under normal circumstances, the serum
concentration of angiopoietin-1 (Ang-1) exceeds Ang-2,
which are the mediators of endothelial function.
Indonesian children showed decreased Ang-1 and in-
creased Ang-2 levels in DHF/DSS [60]. Von Willebrand
factor (vWF), a disintegrin and metalloproteinase with
thrombospondin-1-like domains (ADAMTS-13) and
thrombomodulin (TM) are components of coagulation
system. Both vWF and ADAMTS-13 are synthesized
and released by the ECs and the former stabilizes the ad-
hesion of platelets at the site of vascular injury while the
latter inhibits thrombin formation [61, 62]. Children
with acute dengue infection have elevated vWF levels
and the levels were particularly higher in DSS patients
while ADAMTS-13 levels were decreased in children
with DHF/DSS [63]. TM is present in large quantities on
the surface of endothelium and acts as an anticoagulant.
Serum level of sTM is proposed as diagnostic and prog-
nostic marker of endothelial activation and dysfunction.
Children from Thai and Vietnamese population show in-
creased sTM levels particularly in children with severe
dengue disease [64, 65]. Soluble forms of cell surface
molecules such as sE-selectin, intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) are released from ECs after acti-
vation and are used as diagnostic and prognostic
markers in infectious diseases. sICAM and sVCAM-1
but not sE-selectin were found to be elevated in DSS as
compared to DF and their levels do not differ between
DHF and DSS [20, 66, 67]. The vascular endothelial
growth factor (VEGF) is a potent stimulator of endothe-
lial permeability and promotes proliferation, migration
and survival of ECs. VEGF may contribute to inflamma-
tion and coagulation by inducing the expression of cell
adhesion molecules that promotes adhesion of leuco-
cytes. VEGFRI and VEGFRII are expressed on the ECs
[68]. The VEGF and VEGFR1 plasma levels were signifi-
cantly higher in DHF and DSS than those in DF while
VEGFRII levels were decreased in DHF/DSS compared
to DF. [28, 69] Thus, increase in Ang-2, vWF, sVCAM,
VEGF and VEGFR1 levels and decrease in Ang-1,
ADAMTS-13 and VEGFRII levels might serve as bio-
markers of severe dengue disease.
Biochemical markers as predictors of severe dengue
disease
Several biochemical compounds are shown to be either
elevated or decreased in serum/plasma of patients with
severe dengue and quantifying them might serve as bio-
markers of severe dengue disease. Levels of total plasma
cholesterol, high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) were significantly decreased in
children with the severest disease compared with
patients with mild DHF. [70] Microbial translocation
occurs during severe DENV infection and lipopolysac-
charide (LPS) levels are significantly increased in dengue
patients which is indicated by elevated levels of LPS
binding protein (LBP) and soluble CD14 (sCD14). Ele-
vated LPS levels in dengue patients were found to cor-
relate with clinical disease severity [38]. Liver injury is
associated with severe dengue disease with the increase
in serum aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), gamma-glutamyl transpeptidase, al-
kaline phosphatase, and serum albumin concentrations.
Reports showed that the AST and ALT levels were high
in severe disease and may serve as predictors of severe
disease [32, 33, 71]. Children with DSS and liver injury
have lower zinc levels and the low levels were probably
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caused by loss from diarrhea and from zinc translocating
to liver cells [72]. The Inter-α Inhibitor Proteins (IaIp)
belong to a family of serine protease inhibitors and its
concentrations in pediatric patients suffering from se-
vere DENV infection were significantly lower than in pa-
tients with mild DF and healthy controls [73]. NO is
known to have a strong immunoregulatory role and in
adjusting the diameter of blood vessels, remodeling
blood vessels, inhibiting leukocyte adhesion, platelet ag-
gregation, and contractile cell proliferation [74]. Serum
NO levels in DHF patients were shown to be signifi-
cantly lower than those of the DF patients [33, 75].
Thus, increased levels of LPS, AST, ALT and decreased
levels of lipids, IaIp and NO might serve as markers of
severe dengue disease.
Host genetic markers as predictors of severe
dengue disease
DNA microarrays have been used as a tool to identify
genes and predict patient’s outcome for bacterial and
viral infection [76]. Differential expression of genes has
been shown in DF and DHF/DSS patients and hence can
serve as markers of severe dengue [77, 78]. A recent
study showed that analysis of seven genes (LOC286087,
SLC4A4, PSPH, MYOM2, CACNA2D3, CD244 mol-
ecule, SMAD5) could possibly predict severe dengue
since their expression profile was significantly lower in
DHF patients compared to patients with DF. [79] DENV
infection can trigger apoptosis in a variety of cell types
and apoptotic cells are the main source of cell-free DNA
into the circulatory system [21, 80]. Circulating DNA
levels were significantly higher in patients with DENV infec-
tion than with other febrile illnesses and the increase of
DNA levels can be correlated with disease severity [81].
Conclusion
The usage of the four classes of biomarkers has advan-
tages and limitations. Molecular markers can be accur-
ate. However, it involves high cost for the sequencer and
reagents. Immunological markers which are also seen in
other inflammatory diseases require flow cytometry ana-
lysis. Although the cost of the instrument has come
down, the costs of reagents are still very high for dengue
endemic countries. Endothelial activation and biochem-
ical markers are easy to estimate and the cost is low.
However, the levels are modified in other disease
Table 1 Biomarkers of severe dengue disease
Class Biomarker Change Reference
1. Immune activation markers Cells Plasmacytoid dendritic cells Decrease 14
Lymphocytes Decrease 18, 20
Platelets Decrease 18, 32, 33
Cytokines IL-10 Increase 32, 40, 44
MIF Increase 39, 45
Chemokines CXCL-10 Increase 46
Complements C3a, C5a Increase 48, 49
Soluble receptors sCD4/8, sIL-2R, sTNFRII Increase 53
Proteases Tryptase and chymase Increase 28
2. Endothelial activation markers Mediators of endothelial Angiopoietin-1 Decrease 60
function Angiopoietin-2 Increase 60
Coagulation pathway von Willebrand factor Increase 63
components ADAMTS-13 Decrease 63
sThrombomodulin Increase 64, 65
Cell surface adhesion molecules sICAM, sVCAM Increase 20, 66, 67
Permeability mediators VEGF, VEGFRI Increase 28, 69
VEGFRII Decrease 28, 69
3. Biochemical markers Lipids Total cholesterol, HDL, LDL Decrease 70
LPS LPB, CD14 Increase 38
Liver enzymes AST, ALT Increase 32, 33, 71
Serine protease IaIp Decrease 73
Other soluble substances Nitric oxide Decrease 33, 75
4. Genetic markers Gene profile Certain gene expression Decrease 77–79
Circulating cell free-DNA Increase 81
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conditions as well. Therefore, determination of combin-
ation of biomarkers will be beneficial in predicting se-
vere dengue disease. As shown in the table 1,
information on lymphocyte and platelet counts, levels of
IL-10 and MIF, levels of AST and ALT, levels of gene ex-
pression and cell free DNA will aid in predicting severe
dengue. With the advances in techniques and equip-
ments, multiple biomarker analysis is possible with small
amounts of patient serum samples. However, kinetics
and cut-off levels need to be established particularly for
children and patients in dengue endemic regions.
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